Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

100%

4 of 4 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 4
3(75.0%)
N/A
1(25.0%)
4Total
Phase 4(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT00839540Phase 4Completed

Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins

Role: lead

NCT01401023Not ApplicableCompleted

Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD)

Role: lead

NCT01524302Phase 4Completed

Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia

Role: lead

NCT01401010Phase 4Completed

Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients

Role: lead

All 4 trials loaded